Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Mink Therapeutics Inc (INKT)

Mink Therapeutics Inc (INKT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 58,020
  • Shares Outstanding, K 4,694
  • Annual Sales, $ 0 K
  • Annual Income, $ -9,510 K
  • EBIT $ -11 M
  • EBITDA $ -11 M
  • 60-Month Beta 0.34
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.68
  • Number of Estimates 1
  • High Estimate -0.68
  • Low Estimate -0.68
  • Prior Year -0.62
  • Growth Rate Est. (year over year) -9.68%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.84 +15.31%
on 12/30/25
12.66 -1.23%
on 01/12/26
+0.46 (+3.82%)
since 12/23/25
3-Month
10.51 +18.93%
on 12/04/25
15.25 -18.03%
on 10/24/25
-1.66 (-11.72%)
since 10/23/25
52-Week
4.56 +174.12%
on 01/28/25
76.00 -83.55%
on 07/11/25
+2.75 (+28.19%)
since 01/23/25

Most Recent Stories

More News
MiNK Therapeutics and University of Wisconsin–Madison Announce Phase 1 Clinical Trial of Allo-iNKT Cell Therapy (AgenT-797) to Evaluate Prevention of Graft-Versus-Host Disease

Non-dilutive public-private funded trial with NIAID STTR & Mary Gooze Clinical Trial and Translation Award Expands iNKT platform into transplantation with an off-the-shelf, HLA-independent, lymphodepletion-free...

INKT : 12.50 (+1.13%)
MiNK Therapeutics Announces New Data Showing MiNK-215 Drives Potent Anti-Tumor Activity in Treatment-resistant Solid Tumors

MiNK-215, an IL-15 armoured FAP-targeting CAR-iNKT, targets and clears tumor-protective FAP+ fibroblasts to allow immune cells to infiltrate and kills cancer cells Activates multiple immune pathways...

INKT : 12.50 (+1.13%)
MiNK Therapeutics Reports Q3 2025 Results and Accelerates iNKT Platform Toward Pivotal Development Across Oncology, Pulmonary Disease, and Transplantation

New clinical data show durable remissions and long-tail survivors including >2-year complete remissions in chemotherapy- and checkpoint-refractory cancers GVHD trial launching through non-dilutive funding...

INKT : 12.50 (+1.13%)
MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1–Refractory Solid Tumors at SITC 2025

Durable survival and deep, lasting remissions in checkpoint-refractory, heavily pretreated cancers with median OS of ~23 months with agenT-797 plus anti-PD-1 Evidence of immune activation and tumor-immune...

INKT : 12.50 (+1.13%)
MiNK Therapeutics to Report Third Quarter 2025 Financial Results and Highlight Clinical and Corporate Milestones Advancing iNKT Platform Toward Pivotal Development

NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics , Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies...

INKT : 12.50 (+1.13%)
MiNK Therapeutics to Present Late-Breaking Data on AgenT-797 in Solid Tumors at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting

NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics , Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies...

INKT : 12.50 (+1.13%)
MiNK Therapeutics Appoints Colonel (Ret.) John B. Holcomb, MD, to Board of Directors

NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (Nasdaq: INKT), a clinical-stage biopharmaceutical company pioneering invariant natural killer T (iNKT) cell therapies, today announced...

INKT : 12.50 (+1.13%)
MiNK Therapeutics Dr. Jennifer Buell to Deliver Featured Plenary at 10th Annual CAR-TCR Summit in Boston, MA

NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (Nasdaq: INKT), a clinical-stage biopharmaceutical company pioneering invariant natural killer T (iNKT) cell therapies, today announced...

INKT : 12.50 (+1.13%)
MiNK Therapeutics Appoints Dr. Terese C. Hammond to Accelerate iNKT Pipeline to Pivotal Development

Imminent launch of grant-funded clinical trial in graft-versus-host disease (GVHD) Advancing clinical program in severe pulmonary inflammatory disease NEW YORK, Sept. 18, 2025 (GLOBE NEWSWIRE)...

INKT : 12.50 (+1.13%)
New Strong Sell Stocks for August 22nd

Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today:MiNK Therapeutics, Inc. INKT is a clinical stage biotechnology company pioneering the discovery, development, and commercialization...

MNR : 11.43 (-0.17%)
CSIQ : 22.43 (+4.57%)
INKT : 12.50 (+1.13%)

Business Summary

MiNK Therapeutics Inc. is a clinical stage biotechnology company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T cell therapies to treat cancer and other immune-mediated diseases. MiNK Therapeutics Inc. is headquartered in New York....

See More

Key Turning Points

3rd Resistance Point 13.79
2nd Resistance Point 13.16
1st Resistance Point 12.83
Last Price 12.50
1st Support Level 11.87
2nd Support Level 11.23
3rd Support Level 10.91

See More

52-Week High 76.00
Fibonacci 61.8% 48.71
Fibonacci 50% 40.28
Fibonacci 38.2% 31.85
Last Price 12.50
52-Week Low 4.56

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar